Key result
PlmCas12e cleavage activity on the CCR5 gene varied with target site and guide RNA length, demonstrating a PAM preference for purines over pyrimidines in the fourth position.
Why the study?
Optimal conditions for PlmCas12e cleavage of CCR5, an important target for HIV-1 resistance therapies, were unknown regarding guide RNA lengths and PAM sequences.
PlmCas12e shows a PAM preference for purines over pyrimidines in the fourth position, optimizing conditions for CCR5 gene editing.
CRISPR/Cas is under development as a therapeutic tool for the cleavage, excision, and/or modification of genes in eukaryotic cells. While much effort has focused on CRISPR/Cas from Streptococcus pyogenes (SpCas9) and Staphylococcus aureus (SaCas9), alternative CRISPR systems have been identified using metagenomic datasets from non-pathogenic microbes, including previously unknown class 2 systems, adding to a diverse toolbox of gene editors. The Cas12e (CasX1, CasX2) endonucleases from non-pathogenic Deltaproteobacteria (DpeCas12e) and Planctomycetes (PlmCas12e) are more compact than SpCas9, have a more selective protospacer adjacent motif (PAM) requirement, and deliver a staggered cleavage cut with 5-7 base overhangs. We investigated varying guide RNA (spacer) lengths and alternative PAM sequences to determine optimal conditions for PlmCas12e cleavage of the cellular gene CCR5 (CC-Chemokine receptor-5). CCR5 encodes one of two chemokine coreceptors required by HIV-1 to infect target cells, and a mutation of CCR5 (delta-32) is responsible for HIV-1 resistance and reported cures following bone marrow transplantation. Consequently, CCR5 has been an important target for gene editing utilizing CRISPR, TALENs, and ZFNs. We determined that CCR5 cleavage activity varied with the target site, guide RNA length, and the terminal nucleotide in the PAM sequence. Our analyses demonstrated a PlmCas12e PAM preference for purines (A, G) over pyrimidines (T, C) in the fourth position of the CasX2 PAM (TTCN). These analyses have contributed to a better understanding of CasX2 cleavage requirements and will position us more favorably to develop a therapeutic that creates the delta-32 mutation in the CCR5 gene in hematopoietic stem cells.
No takes yet. Share an insight, caveat, or question.
Armstrong et al. (2023) studied HIV-1 resistance (CCR5 gene editing). PlmCas12e (CasX2) with varying guide RNA lengths and PAM sequences was evaluated on CCR5 cleavage activity. PlmCas12e cleavage activity on the CCR5 gene varied with target site and guide RNA length, demonstrating a PAM preference for purines over pyrimidines in the fourth position.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: